CD274 and non-small cell lung carcinoma: Researchers hypothesized that AZA combined with the blockade of PD-1 may augment immune responses in NSCLC models by turning immune inhibition into immune activation, especially in NSCLC models with low expression of PD-1/PD-L1 pathway modulators [49].